← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
DUGGAN ROBERT W
10% Owner | Chief Executive Officer | Director | Officer
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001055919
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 5
- Purchases · 24M
- 10
- Average purchase
- $8.9M
- Median purchase
- $2.1M
- Gross purchase value
- $89.4M
Companies: PULSE BIOSCIENCES, INC. | Summit Therapeutics Inc.
10 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-06-12 | Summit Therapeutics Inc. | SMMT | Chief Executive Officer | Officer | $50.0M | Open filing |
| 2026-06-04 | Summit Therapeutics Inc. | SMMT | Chief Executive Officer | Officer | $1.5M | Open filing |
| 2026-05-15 | PULSE BIOSCIENCES, INC. | PLSE | Director | 10% Owner | $13.0M | Open filing |
| 2026-05-11 | PULSE BIOSCIENCES, INC. | PLSE | Director | 10% Owner | $13.0M | Open filing |
| 2025-10-23 | Summit Therapeutics Inc. | SMMT | Chief Executive Officer | Officer | $500.0K | Open filing |
| 2025-09-12 | PULSE BIOSCIENCES, INC. | PLSE | Director | 10% Owner | $2.8M | Open filing |
| 2025-09-11 | Summit Therapeutics Inc. | SMMT | Chief Executive Officer | Officer | $6.0M | Open filing |
| 2024-12-17 | PULSE BIOSCIENCES, INC. | PLSE | Director | 10% Owner | $949.3K | Open filing |
| 2024-12-17 | PULSE BIOSCIENCES, INC. | PLES | Director | 10% Owner | $777.8K | Open filing |
| 2024-12-13 | PULSE BIOSCIENCES, INC. | PLSE | Director | 10% Owner | $972.3K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 9Developing | 90.0% (9/10) | 66.7% (6/9) | +2.7% | +5.7% | -9.3% |
| 20D | 9Developing | 90.0% (9/10) | 77.8% (7/9) | +7.9% | +9.1% | -9.4% |
| 60D | 9Developing | 90.0% (9/10) | 44.4% (4/9) | -6.1% | +15.8% | -12.5% |
| 120D | 5Developing | 83.3% (5/6) | 40.0% (2/5) | -2.2% | +1.5% | -23.9% |
Research patterns
- First purchase in 12M
- 0/8
- Large purchase ≥ $100k
- 10/10
- Cluster buying · 15D
- 6/10
- Buying the dip
- 7/9
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.